SRR1516072
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.330
- KRAS_SIGNALING_DN+0.010
- MYOGENESIS-0.040
- DNA_REPAIR-0.090
- PI3K_AKT_MTOR_SIGNALING-0.100
- APICAL_SURFACE-0.120
- PEROXISOME-0.140
- SPERMATOGENESIS-0.140
- TGF_BETA_SIGNALING-0.140
- HEME_METABOLISM-0.150
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.550
- INFLAMMATORY_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.490
- INTERFERON_GAMMA_RESPONSE-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- E2F_TARGETS-0.450
- IL6_JAK_STAT3_SIGNALING-0.450
- KRAS_SIGNALING_UP-0.450
- INTERFERON_ALPHA_RESPONSE-0.430
- G2M_CHECKPOINT-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | aMVAC.P_005_TURBT_S223 | — | — | 0.939 |
| 2 | SRR12202498 | — | — | 0.938 |
| 3 | TCGA-E9-A245-01A-22R-A16F-07 | — | B | 0.930 |
| 4 | SRR1341605 | GTEX | — | 0.925 |
| 5 | SRR650165 | — | — | 0.924 |
| 6 | SRR650197 | — | — | 0.923 |
| 7 | SRR23303752 | — | — | 0.923 |
| 8 | 50f58d2f-7e67-40d8-a35c-a3e2c0bbe457 | — | — | 0.921 |
| 9 | TCGA-FD-A43X-01A-11R-A23W-07 | — | — | 0.920 |
| 10 | SRR1433644 | GTEX | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 2 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |